Cerevel Therapeutics sank -2.3% this afternoon, compared to the S&P 500's day change of 0.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:
-
Cerevel Therapeutics has logged a 27.5% 52 week change, compared to 25.5% for the S&P 500
-
CERE has an average analyst rating of hold and is -7.14% away from its mean target price of $43.4 per share
-
Its trailing earnings per share (EPS) is $-2.73, which brings its trailing Price to Earnings (P/E) ratio to -14.8. The Health Care sector's average P/E ratio is 27.53
-
The company's forward earnings per share (EPS) is $-2.8 and its forward P/E ratio is -14.4
-
The company has a Price to Book (P/B) ratio of 12.99 in contrast to the Health Care sector's average P/B ratio is 3.61
-
The current ratio is currently 10.9, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $-346109000 and the average free cash flow growth rate is -47.1%